Skip to main content
RGNT logo

Regentis Biomaterials Ltd.

RGNTNYSEAMERICANHealthcareMedical Instruments & Supplies

$1.49Today:- (-)

As of Oct 16, 2026 close

Market cap
$9.23M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.23$15.50
Volume (live)
-
Avg. volume (3M)
54.67K

Regentis Biomaterials (RGNT) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Regentis Biomaterials reported total assets of $7.62M and total liabilities of $2.87M. Shareholders' equity was $4.74M. Total debt stood at $1.20M against $7.38M in cash and short-term investments, a net cash position of $6.18M. That puts debt-to-equity at 0.25.

Regentis Biomaterials Balance Sheet Analysis

Values in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Regentis Biomaterials Ltd. (RGNT) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Current Assets
Cash and Cash Equivalents7.380.230.351.242.741.38
Cash & Short-Term Investments7.380.230.351.242.741.38
Accounts Receivable0.230.070.010.030.050.01
Inventory------
Other Current Assets0.240.250.020.480.37-
Total Current Assets7.620.480.361.723.121.39
Non-Current Assets
Property, Plant & Equipment (Net)------
Other Non-Current Assets------
Total Non-Current Assets------
Total Assets7.620.480.361.723.121.39
Current Liabilities
Accounts Payable0.270.250.350.210.310.33
Short-Term Debt1.204.950.216.47--
Current Portion of Long-Term Debt-4.37-6.476.08-
Accrued Liabilities1.411.130.520.420.20-
Deferred Revenue--2.051.982.211.21
Other Current Liabilities-0.160.000.690.790.00
Total Current Liabilities2.876.493.142.612.721.54
Non-Current Liabilities
Long-Term Debt--7.416.476.080.47
Other Non-Current Liabilities--0.620.690.790.70
Total Non-Current Liabilities-35.1043.1341.1740.87-
Total Liabilities2.8741.5946.2743.7843.602.71
Stockholders' Equity
Retained Earnings-55.79-42.15-46.95-42.82-41.23-36.09
Additional Paid-in Capital60.541.041.040.750.75-
Shares Outstanding5.185.184.934.934.93-
Total Stockholders' Equity4.74-41.10-45.91-42.06-40.48-1.33
Total Liabilities & Equity7.620.480.361.723.12-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Regentis Biomaterials Balance Sheet

How much debt does Regentis Biomaterials have?

Regentis Biomaterials had total debt of $1.20M as of Dec 31, 2025, against $7.38M in cash and short-term investments. Its debt-to-equity ratio was 0.25. Total debt was $4.95M a year earlier.

What are Regentis Biomaterials's total assets?

Regentis Biomaterials reported total assets of $7.62M as of Dec 31, 2025, up 1480.5% from $482.00K a year earlier. Total liabilities were $2.87M.

What is Regentis Biomaterials's shareholders' equity?

Regentis Biomaterials's shareholders' equity was $4.74M as of Dec 31, 2025, or about $0.92 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition